FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.
What happened
FDA reviewed records Sanrace submitted after FDA's September 9, 2025 request under section 704(a)(4) of the FD&C Act; this was a records review, not an onsite inspection. FDA found the firm did not test incoming components for identity, lacked process validation, and had an inadequate quality unit and stability program. FDA placed all drugs from the firm offered for import into the United States on Import Alert 66-40 on September 21, 2026.
What FDA found
Did not test each incoming component for identity, including an active ingredient that needed testing for a hazardous impurity.
21 CFR 211.84(d)(1)Had no written production and process control procedures and no process validation procedures or studies.
21 CFR 211.100(a)Quality unit lacked responsibility and authority to approve or reject components and drug products.
21 CFR 211.22(a)Laboratory control procedures and system monitoring were inadequate to ensure identity, strength, quality, and purity.
21 CFR 211.160(b)Stability program was inadequate; records lacked viscosity, pH, assay, and microbiological testing over shelf life.
21 CFR 211.166(a)
What FDA wants
FDA asks the firm to respond in writing within 15 business days, address the violations and root causes with corrective actions, and consider engaging a qualified CGMP consultant; FDA may withhold approvals and refuse imports until compliance is confirmed.
Who should pay attention
- brands that rely on this contract manufacturer for OTC drugs
- US importers of OTC drug products
- supplier quality teams auditing Chinese drug manufacturers
This is a summary. Read the original letter on fda.gov.